Transformative Biotech

Breakthrough PCR Testing for Infectious Diseases Anytime, @ANYWHERE™

Learn About our Direct-to-PCR Technology

$13M global deaths annually from infectious diseases.
47% of the world lacks access to diagnostics.
80% of U.S. counties have no infectious disease specialist.

Rapid diagnosis is the first line of defense.

pcr test

We are seeking commercialization partners who are looking to deploy this disruptive PCR technology.

We are looking for commercialization partners who share our belief in the transformative potential of this technology. Our partners will find themselves at the forefront of a new and exciting era in PCR, providing customers with game-changing solutions that offer unprecedented speed, precision, and sensitivity.

We welcome any interested parties to contact us for further information on how we can work together to bring this innovative technology to market. With a proven track record of innovation and a deep commitment to excellence, we are confident in our ability to deliver a high-quality, reliable product that can transform the way researchers and scientists approach PCR. Join us in this exciting journey and experience the transformative potential of our next-generation PCR technology first-hand.

  • Create dramatic cost savings through direct-to-PCR testing for infectious pathogens, including viruses and bacteria;
  • Offer the ability to collect different sample types, such as nasal swab or saliva samples, and test for infectious pathogens, such as viruses or bacteria;
  • Enable molecular diagnostic testing for infectious pathogens in at-home or doctors’ office/point-of-care settings;
  • Test for more than one pathogen in one sample with multiplex capability;
  • Enable determination of viral load in swab or saliva samples, empowering physicians to treat patients more effectively.
Learn More

Our Technology

Our proprietary buffer products release and protect DNA/RNA at the point of collection, enabling direct input into PCR.

Proven in more then 590,000 tests in a CLIA-certified lab generating $14M in revenue.

Protected Innovation. Global Reach.

Patent issued for landmark extraction-free pathogen detection — July 1, 2025.


With five additional patents pending, our direct-to-PCR buffer technology is protected and positioned for global impact.
Built to support rapid, lab-free diagnostics anytime, @ANYWHERE™.

IMPORTANT

Industry News